The use of COA in patient-centered drug development: part 1 2a193b

From introduction to interpretation, Dan O’Connor and Chad Gwaltney as they explore how best to meet the expectations of regulatory authorities. Including: demystifying COA guidance documents and discussing how they became an integral part of the regulatory landscape. w4n3m